Fus (Fused In Sarcoma) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.[1]
FUS (Fused in Sarcoma), also known as TLS (Translocated in Liposarcoma), is a multifunctional RNA-binding protein encoded by the FUS gene on chromosome 16p11.2. It belongs to the FET family of proteins (FUS, EWSR1, TAF15) and plays essential roles in DNA repair, transcription regulation, RNA splicing, and RNA transport. FUS was first identified as part of a chromosomal translocation in human myxoid liposarcoma,[1:1] but gained prominence in neurodegeneration research when mutations in FUS were identified as causative for familial ALS[2][3] and FTD.
FUS is a 526-amino acid protein that is predominantly nuclear in healthy neurons but mislocalizes to the cytoplasm in disease states, where it forms pathological aggregates through aberrant liquid-liquid phase separation (LLPS). Mutations in FUS account for approximately 4–5% of familial ALS cases and are particularly associated with aggressive juvenile-onset forms of the disease.[4] FUS pathology is also found in a subset of FTD cases lacking tau or TDP-43 inclusions, classified as FTLD-FUS.[5]
FUS is a 526-amino acid protein with a modular domain architecture that is asymmetrically divided into a low complexity domain (LCD) and an RNA-binding domain (RBD):[6]
QGSY-rich prion-like domain (PrLD, residues 1–165): An intrinsically disordered N-terminal region enriched in glutamine, glycine, serine, and tyrosine residues. This domain mediates liquid-liquid phase separation and is critical for FUS self-assembly into biomolecular condensates. Post-translational modifications including phosphorylation regulate its phase behavior.[7]
RGG1 domain (residues 165–267): The first arginine-glycine-glycine repeat region, which contributes to RNA binding and phase separation through electrostatic interactions.
RNA Recognition Motif (RRM, residues 285–370): A canonical RNA-binding domain that recognizes specific RNA motifs including GGUG and GUGGU sequences.[8]
RGG2 domain (residues 370–422): The second RGG repeat region.
Zinc finger domain (ZnF, residues 422–453): A C2/C2-type zinc finger that binds both RNA and DNA and contributes to nucleic acid binding specificity.
RGG3 domain (residues 453–501): The third RGG repeat region.
Nuclear Localization Signal (NLS, residues 510–526): A PY-NLS at the C-terminus recognized by the nuclear import receptor Transportin-1 (TNPO1/Karyopherin-β2). Most ALS-causing mutations cluster in or near this domain, disrupting nuclear import.[9]
FUS is one of the most abundant RNA-binding proteins in the nucleus and participates in virtually every step of RNA metabolism:[10]
FUS rapidly localizes to sites of DNA damage, where it facilitates the DNA damage response (DDR).[12] Through its interaction with poly(ADP-ribose) (PAR), FUS is recruited to DNA double-strand breaks within seconds, preceding other repair factors. FUS facilitates both homologous recombination and non-homologous end joining repair pathways. Impaired DNA damage repair has been demonstrated in cortical neurons from ALS patients carrying FUS mutations, linking FUS dysfunction to genomic instability and neurodegeneration.[6:1]
Under cellular stress, FUS is recruited to stress granules (SGs)—cytoplasmic ribonucleoprotein assemblies that temporarily halt translation of non-essential mRNAs. FUS contributes to SG assembly through its prion-like domain.[13] Pathological mutations promote persistent SG formation and impair SG disassembly, potentially serving as nucleation sites for irreversible FUS aggregation.[6:2]
FUS has become a paradigmatic protein for studying biomolecular condensate formation through liquid-liquid phase separation (LLPS):[14]
Normal LLPS: FUS undergoes reversible phase separation to form dynamic liquid-like droplets in the nucleus, where it participates in transcription hubs, DNA repair foci, and paraspeckles. The prion-like LCD drives droplet formation, while the RBD modulates condensate properties through RNA engagement.
Aberrant Phase Transitions: Under pathological conditions—including disease-associated mutations, elevated protein concentration, or prolonged stress—FUS droplets undergo maturation from liquid to gel to solid states, forming amyloid-like fibrils.[15] This irreversible "aging" of condensates is a key step in pathological aggregation.
Regulation: FUS phase behavior is modulated by post-translational modifications (phosphorylation of serine residues in the LCD by DNA-PK reduces LLPS), RNA binding (RNA opposes aggregation at physiological concentrations), and chaperone activity (DNAJB6 can maintain FUS in a loose gel-like state, preventing fibrilization).[16]
Mutations in FUS cause approximately 4–5% of familial ALS and ~1% of sporadic ALS cases. Over 50 disease-associated mutations have been identified, with the majority clustering in the C-terminal NLS domain:[17]
FUS-ALS shows two distinct pathological patterns correlating with disease severity: (1) early-onset aggressive disease with basophilic inclusions and round FUS-immunoreactive neuronal cytoplasmic inclusions (P525L, R522G), and (2) later-onset disease with tangle-like inclusions and frequent glial cytoplasmic inclusions (R521C).[19]
FUS pathology defines a subset of FTD known as FTLD-FUS, which accounts for approximately 9% of all FTLD cases with ubiquitin-positive inclusions.[5:1] Three subtypes are recognized:
Notably, unlike FUS-ALS, FTLD-FUS cases rarely harbor FUS mutations, suggesting a different pathogenic mechanism involving wild-type FUS aggregation.[5:2]
ASOs targeting FUS mRNA to reduce FUS protein levels have shown promise in preclinical models. Intrathecal delivery of FUS-targeting ASOs reversed motor neuron degeneration in mouse models.[21] Jacifusen (ION363), an ASO targeting FUS, was the first personalized ASO therapy administered to an ALS patient under compassionate use.[22]
Molecular chaperones that prevent aberrant FUS phase transitions represent a promising therapeutic avenue. DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity.[16:1] Heat shock proteins and the ubiquitin-proteasome system are also being explored as strategies to clear FUS aggregates.
Compounds that stabilize FUS in its liquid-like state and prevent aberrant solid-state transitions are under investigation. Targeting the Transportin-1–FUS interaction to restore nuclear import is another active area of drug discovery.
FUS shares structural and functional similarities with TDP-43, another RNA-binding protein implicated in ALS and FTD. Both proteins contain prion-like domains and undergo pathological phase transitions. However, FUS and TDP-43 pathology are generally mutually exclusive in patient tissues, suggesting parallel but distinct disease pathways.[23]
FUS also interacts with SOD1, another ALS-associated protein. Co-aggregation of FUS with other RNA-binding proteins, including hnRNPA1, hnRNPA2/B1, and EWSR1, has been observed in disease models, indicating that FUS toxicity may extend beyond the protein itself to a broader disruption of RNA metabolism.[24]
Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993. ↩︎ ↩︎
Kwiatkowski TJ Jr, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009. ↩︎
Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009. ↩︎
Mackenzie IR, Rademakers R, Neumann M. TAR DNA-binding protein 43 in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010. ↩︎
Neumann M, et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009. ↩︎ ↩︎ ↩︎
Kato M, et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012. ↩︎ ↩︎ ↩︎
Monahan Z, et al. Phosphorylation of the FUS low-complexity domain by DNA-PK regulates its phase separation and pathogenic aggregation. Nat Neurosci. 2017. ↩︎
Lerga A, et al. Identification of an RNA binding specificity for the FUS/TLS protein. J Biol Chem. 2001. ↩︎
Dormann D, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010. ↩︎ ↩︎
Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS: a nuclear affair. Trends Neurosci. 2012. ↩︎
Fusco CM, et al. FUS modulates Drosha and Dicer-mediated microRNA biogenesis. Nat Neurosci. 2012. ↩︎
Mastrocola AS, et al. The RNA-binding protein fused in sarcoma (FUS) functions downstream of poly(ADP-ribose) polymerase (PARP) in response to DNA damage. J Biol Chem. 2013. ↩︎
Li YR, et al. Stress granules as crucibles of ALS pathogenesis. J Cell Biol. 2013. ↩︎
Patel A, et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015. ↩︎
Murakami T, et al. ALS mutations in FUS cause neuronal death and accelerate formation of stress granules. Neuron. 2015. ↩︎
Peking University et al. DNAJB6 inhibits phase separation and neurotoxicity of ALS-linked FUS. Nat Commun. 2025. ↩︎ ↩︎
Shang Y, Huang EJ. Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. Brain Res. 2016. ↩︎
Conte A, et al. P525L FUS mutation is consistently associated with a severe form of juvenile Amyotrophic Lateral Sclerosis. Neuromuscul Disord. 2012. ↩︎
Mackenzie IR, et al. Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations. Acta Neuropathol. 2011. ↩︎
Nomura T, et al. Intracellular membrane damage by FUS pathology spreads through prion-like propagation. Acta Neuropathol. 2014. ↩︎
Korobeynikov VA, et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022. ↩︎
First personalized antisense oligonucleotide therapy for FUS-associated ALS. Nat Med. 2022. ↩︎
Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013. ↩︎
Kim HJ, et al. Therapeutic modulation of eIF2α phosphorylation rescues FUS-linkedALS phenotypes in a Drosophila model. Nat Commun. 2013. ↩︎